188 related articles for article (PubMed ID: 28052121)
1. Molecular Characteristics of High-Dose Melphalan Associated Oral Mucositis in Patients with Multiple Myeloma: A Gene Expression Study on Human Mucosa.
Marcussen M; Bødker JS; Christensen HS; Johansen P; Nielsen S; Christiansen I; Bergmann OJ; Bøgsted M; Dybkær K; Vyberg M; Johnsen HE
PLoS One; 2017; 12(1):e0169286. PubMed ID: 28052121
[TBL] [Abstract][Full Text] [Related]
2. Use of sidestream dark-field (SDF) imaging for assessing the effects of high-dose melphalan and autologous stem cell transplantation on oral mucosal microcirculation in myeloma patients.
Milstein DM; te Boome LC; Cheung YW; Lindeboom JA; van den Akker HP; Biemond BJ; Ince C
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 Jan; 109(1):91-7. PubMed ID: 20123381
[TBL] [Abstract][Full Text] [Related]
3. Variability of high-dose melphalan exposure on oral mucositis in patients undergoing prophylactic low-level laser therapy.
Rodrigues GH; Jaguar GC; Alves FA; Guollo A; Camandoni VO; Damascena AS; Lima VCC
Lasers Med Sci; 2017 Jul; 32(5):1089-1095. PubMed ID: 28512727
[TBL] [Abstract][Full Text] [Related]
4. Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy--European Blood and Marrow Transplantation Mucositis Advisory Group.
Blijlevens N; Schwenkglenks M; Bacon P; D'Addio A; Einsele H; Maertens J; Niederwieser D; Rabitsch W; Roosaar A; Ruutu T; Schouten H; Stone R; Vokurka S; Quinn B; McCann S;
J Clin Oncol; 2008 Mar; 26(9):1519-25. PubMed ID: 18268357
[TBL] [Abstract][Full Text] [Related]
5. Oral mucositis in myeloma patients undergoing melphalan-based autologous stem cell transplantation: incidence, risk factors and a severity predictive model.
Grazziutti ML; Dong L; Miceli MH; Krishna SG; Kiwan E; Syed N; Fassas A; van Rhee F; Klaus H; Barlogie B; Anaissie EJ
Bone Marrow Transplant; 2006 Oct; 38(7):501-6. PubMed ID: 16980998
[TBL] [Abstract][Full Text] [Related]
6. Oral mucositis and outcomes of autologous hematopoietic stem-cell transplantation following high-dose melphalan conditioning for multiple myeloma.
Vera-Llonch M; Oster G; Ford CM; Lu J; Sonis S
J Support Oncol; 2007 May; 5(5):231-5. PubMed ID: 17564153
[TBL] [Abstract][Full Text] [Related]
7. Icing oral mucositis: Oral cryotherapy in multiple myeloma patients undergoing autologous hematopoietic stem cell transplant.
Chen J; Seabrook J; Fulford A; Rajakumar I
J Oncol Pharm Pract; 2017 Mar; 23(2):116-120. PubMed ID: 26684614
[TBL] [Abstract][Full Text] [Related]
8. A Phase IIb, Multicenter, Open-Label, Safety, and Efficacy Study of High-Dose, Propylene Glycol-Free Melphalan Hydrochloride for Injection (EVOMELA) for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation.
Hari P; Aljitawi OS; Arce-Lara C; Nath R; Callander N; Bhat G; Allen LF; Stockerl-Goldstein K
Biol Blood Marrow Transplant; 2015 Dec; 21(12):2100-2105. PubMed ID: 26327631
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of cryotherapy associated with laser therapy for decreasing severity of melphalan-induced oral mucositis during hematological stem-cell transplantation: a prospective clinical study.
de Paula Eduardo F; Bezinelli LM; da Graça Lopes RM; Nascimento Sobrinho JJ; Hamerschlak N; Correa L
Hematol Oncol; 2015 Sep; 33(3):152-8. PubMed ID: 24519448
[TBL] [Abstract][Full Text] [Related]
10. A prospective, randomized study of cryotherapy during administration of high-dose melphalan to decrease the severity and duration of oral mucositis in patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation.
Lilleby K; Garcia P; Gooley T; McDonnnell P; Taber R; Holmberg L; Maloney DG; Press OW; Bensinger W
Bone Marrow Transplant; 2006 Jun; 37(11):1031-5. PubMed ID: 16633359
[TBL] [Abstract][Full Text] [Related]
11. The Prospective Oral Mucositis Audit: relationship of severe oral mucositis with clinical and medical resource use outcomes in patients receiving high-dose melphalan or BEAM-conditioning chemotherapy and autologous SCT.
McCann S; Schwenkglenks M; Bacon P; Einsele H; D'Addio A; Maertens J; Niederwieser D; Rabitsch W; Roosaar A; Ruutu T; Schouten H; Stone R; Vorkurka S; Quinn B; Blijlevens N;
Bone Marrow Transplant; 2009 Jan; 43(2):141-7. PubMed ID: 18776926
[TBL] [Abstract][Full Text] [Related]
12. The choice of multiple myeloma induction therapy affects the frequency and severity of oral mucositis after melphalan-based autologous stem cell transplantation.
Fleming S; Harrison SJ; Blombery P; Joyce T; Stokes K; Seymour JF; Prince HM; Ritchie D
Clin Lymphoma Myeloma Leuk; 2014 Aug; 14(4):291-6. PubMed ID: 24629850
[TBL] [Abstract][Full Text] [Related]
13. Febrile mucositis in haematopoietic SCT recipients.
van der Velden WJ; Blijlevens NM; Feuth T; Donnelly JP
Bone Marrow Transplant; 2009 Jan; 43(1):55-60. PubMed ID: 18762766
[TBL] [Abstract][Full Text] [Related]
14. Prevention of high dose L-PAM-induced mucositis by cryotherapy.
Dumontet C; Sonnet A; Bastion Y; Salles G; Espinouse D; Coiffier B
Bone Marrow Transplant; 1994 Sep; 14(3):492-4. PubMed ID: 7994283
[No Abstract] [Full Text] [Related]
15. Severe gastrointestinal mucositis following high dose melphalan therapy for multiple myeloma.
Sharma SK; Handoo A; Choudhary D; Dhamija G; Gupta N
World J Gastroenterol; 2013 Feb; 19(5):784-5. PubMed ID: 23429569
[TBL] [Abstract][Full Text] [Related]
16. Cryotherapy for the prevention of high-dose melphalan-induced oral mucositis.
Mori T; Aisa Y; Yamazaki R; Mihara A; Ikeda Y; Okamoto S
Bone Marrow Transplant; 2006 Nov; 38(9):637-8. PubMed ID: 16953203
[No Abstract] [Full Text] [Related]
17. GWAS of 972 autologous stem cell recipients with multiple myeloma identifies 11 genetic variants associated with chemotherapy-induced oral mucositis.
Coleman EA; Lee JY; Erickson SW; Goodwin JA; Sanathkumar N; Raj VR; Zhou D; McKelvey KD; Apewokin S; Stephens O; Enderlin CA; Vangsted AJ; Reed PJ; Anaissie EJ
Support Care Cancer; 2015 Mar; 23(3):841-9. PubMed ID: 25218607
[TBL] [Abstract][Full Text] [Related]
18. Usefulness and safety of oral cryotherapy in the prevention of oral mucositis after conditioning regimens with high-dose melphalan for autologous stem cell transplantation for lymphoma and myeloma.
Batlle M; Morgades M; Vives S; Ferrà C; Oriol A; Sancho JM; Xicoy B; Moreno M; Magallón L; Ribera JM
Eur J Haematol; 2014 Dec; 93(6):487-91. PubMed ID: 24889275
[TBL] [Abstract][Full Text] [Related]
19. Oral mucosa tissue gene expression profiling before, during, and after radiation therapy for tonsil squamous cell carcinoma.
Marcussen M; Sønderkær M; Bødker JS; Andersen M; Nielsen S; Vesteghem C; Christiansen I; Bergmann OJ; Bøgsted M; Dybkær K; Vyberg M; Johnsen HE
PLoS One; 2018; 13(1):e0190709. PubMed ID: 29338018
[TBL] [Abstract][Full Text] [Related]
20. Associations of High-Dose Melphalan Pharmacokinetics and Outcomes in the Setting of a Randomized Cryotherapy Trial.
Cho YK; Sborov DW; Lamprecht M; Li J; Wang J; Hade EM; Gao Y; Tackett K; Williams N; Benson DM; Efebera YA; Rosko AE; Devine SM; Poi M; Hofmeister CC; Phelps MA
Clin Pharmacol Ther; 2017 Sep; 102(3):511-519. PubMed ID: 28160288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
